Literature DB >> 31773636

Cardiac Collapse Secondary to Phenytoin Toxicity in a Neonate Treated with Extracorporeal Membrane Oxygenation Support (ECMO).

Michelle Knecht1, Joseph LaRochelle2, Brian Barkemeyer1, Raegan Gupta1, Michael Brumund3, Christy Mumphrey4.   

Abstract

INTRODUCTION: Although medication toxicity is uncommon in neonates, there are several medications used in this population that pose a risk. Phenytoin has an increased risk of toxicity given its narrow therapeutic window and variations in drug elimination. CASE REPORT: We describe the case of a 3-day-old male infant who developed cardiovascular collapse secondary to severe phenytoin toxicity (max phenytoin level 86 μg/mL) and was placed on extracorporeal membrane oxygenation support (ECMO). Several ancillary treatments were utilized in an attempt to decrease serum phenytoin concentrations and limit toxicity including albumin boluses, phenobarbital administration, intravenous lipid infusion, and folic acid supplementation. DISCUSSION: Although uncommon, drug toxicity should be considered in patients with acute changes who are exposed to medications with potential toxicity. With elevated levels of phenytoin, the half-life can be prolonged resulting in longer exposure to elevated levels of the drug as seen in our patient. This case report highlights the importance of ECMO utilization for cardiac support in neonates with medication toxicity and other potential ancillary treatments to decrease serum phenytoin concentrations.

Entities:  

Keywords:  ECMO; Fosphenytoin; Neonate; Phenytoin

Mesh:

Substances:

Year:  2019        PMID: 31773636      PMCID: PMC7099106          DOI: 10.1007/s13181-019-00742-x

Source DB:  PubMed          Journal:  J Med Toxicol        ISSN: 1556-9039


  10 in total

1.  Fosphenytoin may cause hemodynamically unstable bradydysrhythmias.

Authors:  Bruce D Adams; Neil H Buckley; James Y Kim; Lia B Tipps
Journal:  J Emerg Med       Date:  2006-01       Impact factor: 1.484

2.  Extracorporeal Membrane Oxygenation (ECMO) for Severe Toxicological Exposures: Review of the Toxicology Investigators Consortium (ToxIC).

Authors:  G S Wang; R Levitan; T J Wiegand; J Lowry; R F Schult; S Yin
Journal:  J Med Toxicol       Date:  2016-03

3.  Phenytoin toxicity in two-month-old Thai infant with CYP2C9 gene polymorphism--A case report.

Authors:  Montida Veeravigrom; Vorapol Jaroonvanichkul; Wiracha Netbaramee; Pichaya Phaisarn; Thanita Uyathanarat
Journal:  Brain Dev       Date:  2015-05-18       Impact factor: 1.961

4.  Intralipid emulsion treatment as an antidote in lipophilic drug intoxications.

Authors:  Sebnem Eren Cevik; Tanju Tasyurek; Ozlem Guneysel
Journal:  Am J Emerg Med       Date:  2014-05-21       Impact factor: 2.469

Review 5.  The use of phenobarbital and other anti-seizure drugs in newborns.

Authors:  Mohamed El-Dib; Janet S Soul
Journal:  Semin Fetal Neonatal Med       Date:  2017-08-12       Impact factor: 3.926

Review 6.  Phenytoin poisoning.

Authors:  Simon Craig
Journal:  Neurocrit Care       Date:  2005       Impact factor: 3.210

Review 7.  Pharmacogenetics in pediatrics. Implications for practice.

Authors:  J S Leeder; G L Kearns
Journal:  Pediatr Clin North Am       Date:  1997-02       Impact factor: 3.278

8.  Phenytoin-folic acid interaction: a lesson to be learned.

Authors:  H Seligmann; I Potasman; B Weller; M Schwartz; M Prokocimer
Journal:  Clin Neuropharmacol       Date:  1999 Sep-Oct       Impact factor: 1.592

Review 9.  Extracorporeal Treatment in Phenytoin Poisoning: Systematic Review and Recommendations from the EXTRIP (Extracorporeal Treatments in Poisoning) Workgroup.

Authors:  Kurt Anseeuw; James B Mowry; Emmanuel A Burdmann; Marc Ghannoum; Robert S Hoffman; Sophie Gosselin; Valery Lavergne; Thomas D Nolin
Journal:  Am J Kidney Dis       Date:  2015-11-11       Impact factor: 8.860

10.  Hypocalcemia-like electrocardiographic changes after administration of intravenous fosphenytoin.

Authors:  Mark T Keegan; Lois R Bondy; Joseph L Blackshear; William L Lanier
Journal:  Mayo Clin Proc       Date:  2002-06       Impact factor: 7.616

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.